UG Healthcare Corp. Ltd. (8K7) AI Stock Analysis

• Market Cap: S$61.13M
• Dividend Yield: N/A
• Average Volume (3M): 408.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.72
• Revenue Growth: 25.06%
• EPS Growth: 37.11%
• Country: SG
• Employees: 898
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): >-0.01
• Shares Outstanding: 623,825,800
• 10 Day Avg. Volume: 826,640
• 30 Day Avg. Volume: 408,916
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 47 Neutral
• Price Target: S$0.00 ▼(-100.00% Downside)

UG Healthcare Corp. Ltd. faces significant challenges with profitability and cash flow, which are the most impactful factors on the overall score. Technical indicators show no strong trend, and the valuation is negatively affected by the company's unprofitability. The absence of earnings call data and corporate events means these factors do not influence the score.

UG Healthcare Corp. Ltd. Business Overview & Revenue Model

Company Description

UG Healthcare Corp. Ltd. is a leading manufacturer and supplier of healthcare products, primarily focusing on the production of medical gloves and other personal protective equipment (PPE). Headquartered in Singapore, the company operates in the healthcare sector, providing essential products to hospitals, clinics, and healthcare institutions globally. UG Healthcare is known for its high-quality latex, nitrile, and vinyl gloves, catering to both the medical and non-medical segments. The company also explores opportunities in related healthcare products, positioning itself as a key player in the global healthcare supply chain.

How the Company Makes Money

UG Healthcare Corp. Ltd. generates revenue through the manufacture and sale of medical gloves and PPE. Its primary revenue stream comes from the distribution of these products to various markets, including hospitals, clinics, and retail outlets. The company benefits from economies of scale due to its large production capacity and efficient manufacturing processes. Additionally, UG Healthcare has established partnerships with various distributors and healthcare organizations that enhance its market reach. Factors contributing to its earnings include the growing global demand for medical gloves, particularly heightened by health crises, and the company's commitment to quality and compliance with international standards, which bolster its reputation and customer loyalty.

UG Healthcare Corp. Ltd. Financial Statement Overview

Summary

UG Healthcare Corp. Ltd. is facing financial headwinds with declining revenues and negative profitability metrics, suggesting operational inefficiencies or market challenges. While the balance sheet shows solid equity, increasing leverage is a concern. Cash flow struggles highlight the need for strategic operational improvements to enhance liquidity and profitability.

Income Statement

The company has faced a decline in revenue over recent years, dropping significantly from 2021 to 2023. Despite an increase in revenue from 2023 to 2024, profitability remains a challenge with negative EBIT and net income margins. The gross profit margin has improved but remains insufficient to offset operational losses, indicating potential inefficiencies or cost management issues.

Balance Sheet

The balance sheet shows a relatively strong equity base with a healthy equity ratio. However, the debt-to-equity ratio has increased, indicating rising financial leverage. Despite this, the company maintains a strong cash position, which provides some buffer against financial risks.

Cash Flow

The company is experiencing negative operating and free cash flows, reflecting operational challenges and potential cash management issues. This is concerning as negative cash flows persist, despite a minor improvement in free cash flow from 2023 to 2024.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	94.93M	144.07M	115.20M	101.13M	232.60M	338.40M
Gross Profit	3.43M	34.74M	25.87M	1.45M	84.39M	196.16M
EBITDA	-20.11M	2.47M	-3.86M	-24.53M	53.37M	159.46M
Net Income	-20.93M	-3.79M	-6.06M	-20.73M	36.80M	118.77M
Balance Sheet
Total Assets	215.39M	232.35M	226.45M	230.00M	288.04M	268.29M
Cash, Cash Equivalents and Short-Term Investments	45.13M	23.29M	28.00M	61.74M	100.22M	68.44M
Total Debt	28.46M	47.36M	43.72M	31.13M	17.98M	16.74M
Total Liabilities	44.08M	76.03M	65.17M	48.81M	52.98M	73.53M
Stockholders Equity	171.94M	158.73M	163.39M	180.84M	228.90M	190.64M
Cash Flow
Free Cash Flow	-36.98M	-8.11M	-20.71M	-47.17M	31.63M	61.47M
Operating Cash Flow	-34.35M	-4.78M	-18.16M	-39.14M	53.95M	81.16M
Investing Cash Flow	-2.63M	-3.21M	-22.73M	-8.03M	-21.19M	-18.89M
Financing Cash Flow	4.62M	3.24M	8.36M	8.70M	-973.00K	-3.14M

UG Healthcare Corp. Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:8K7, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.10, and below the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.34 is Neutral, neither overbought nor oversold. The STOCH value of 15.38 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:8K7.

UG Healthcare Corp. Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AP4	76 Outperform	S$1.19B	16.26	16.42%	17.53%	18.55%	-5.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
8K7	47 Neutral	S$61.13M	―	-2.33%	―	25.06%	37.11%